Endo Pharmaceuticals

Nancy J. Wysenski has been appointed chief operating officer, Endo Pharmaceuticals Inc., effective immediately. Ms. Wysenski will oversee the integration and execution of Endo’s operating strategy, sourcing and commercializing its product portfolio, and advancing the company’s organizational capabilities. She will have direct responsibility for business development, strategic alliances, sales and marketing, technical operations and supply chain, and corporate services, including human resources and information management.

Ms. Wysenski most recently served as president of EMD Pharmaceuticals, Inc., the U.S. subsidiary Merck KGaA of Darmstadt, Germany. In this role, she was responsible for U.S. operations for this division and for Dey Laboratories, a specialty respiratory pharmaceutical business. Ms. Wysenski was also responsible for leading the team that secured approval for EMD’s first U.S. product, and served as a member of the Merck KGaA Ethical Pharmaceuticals Executive Committee. She led a variety of global business initiatives, including the Portfolio Management Team based in Germany.

Previous positions include senior vice president of operations at NetGenics and a number of positions of increasing scope and responsibility at Astra Merck. Prior to joining Astra Merck in 1990, she held various positions at Merck Human Health.